Related posts
This Week’s Stock Picks & BNN Top Picks Summary: BN-T, INTU-Q and 23 Stock Top Picks (Mar 15-21)3 Promising Oversold Stocks3 Best U.S. Healthcare ETFsThis summary was created by AI, based on 4 opinions in the last 12 months.
Based on the reviews from different experts, Astrazeneca P L C (AZN-N) seems to have a strong focus on cancer drugs, with recent acquisitions targeting rare diseases and vaccine production. The company's strong business model during the Covid-19 pandemic and significant investments in research and development are contributing to its viability for top-line growth. The stock is perceived as a good long-term hold with attractive entry points and a strong line of R&D products.
Highest growth rate in Pharma sector given current share price. Very attractive entry point (15x earnings). Leader in oncology channels. Chemotherapy products very strong and is a leader in R&D. Good long term hold.
The recently bought Ocosavax (a vaccine-maker) and Gracell (an early-stage Chinese biotech working on cancer treatments).
Very strong business model during the Covid-19 pandemic.
Strong line of R&D products.
Huge revision in research providing viability for top line growth.
Current share price presenting good buying opportunity.
Continues to own shares.
Astrazeneca P L C is a American stock, trading under the symbol AZN-N on the New York Stock Exchange (AZN). It is usually referred to as NYSE:AZN or AZN-N
In the last year, 1 stock analyst published opinions about AZN-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Astrazeneca P L C.
Astrazeneca P L C was recommended as a Top Pick by on . Read the latest stock experts ratings for Astrazeneca P L C.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Astrazeneca P L C In the last year. It is a trending stock that is worth watching.
On 2024-03-28, Astrazeneca P L C (AZN-N) stock closed at a price of $67.92.
They focus on cancer drugs and making massive inroads. AZN just bought Alexion, which seeks drugs for rare diseases, so the target markets are there. AZN sells at 15x PE with earnings to grow 5-10%. Dividend pays 3.5%.
(Analysts’ price target is $83.88)